Phanes Completes Phase 2 Enrollment for Spevatamig in PDAC
SAN DIEGO, California, June 22, 2026 Phanes Therapeutics has announced the successful completion of patient enrollment in its Phase...
CIS
Advertisement
Hamlet BioPharma Expands Alpha1H Trial for Bladder Cancer
LUND, Sweden, June 22, 2026 Hamlet BioPharma AB has announced a significant expansion of its U.S. clinical development program...
ImmunityBio’s ANKTIVA Expansion Review Accepted by FDA
CULVER CITY, Calif., May 19, 2026 ImmunityBio announced that the U.S. Food and Drug Administration (FDA) has accepted its...
FDA Approves J&J’s INLEXZO™, Redefining Bladder Cancer Care
September 9, 2025 – Raritan, N.J. – In a landmark regulatory milestone, Johnson & Johnson (NYSE: JNJ) announced U.S....
Advertisement
